Thyristor-Bypassed Sub-Module Power-Groups for Achieving High-Efficiency, DC Fault Tolerant Multilevel VSCs

Achieving DC fault tolerance in modular multilevel converters requires the use of a significant number of Sub-Modules (SMs) which are capable of generating a negative voltage. This results in an increase in the number of semiconductor devices in the current path, increasing converter conduction losses. This paper introduces a thyristor augmented multilevel structure called a Power-Group (PG), which replaces the stacks of SMs in modular converters. Each PG is formed out of a series stack of SMs with a parallel force-commutated thyristor branch, which is used during normal operation as a low loss bypass path in order to achieve significant reduction in overall losses. The PG also offers negative voltage capability and so can be used to construct high efficiency DC fault tolerant converters. Methods of achieving the turn-on and turn-off of the thyristors by using voltages generated by the parallel stack of SMs within each PG are presented, while keeping both the required size of the commutation inductor, and the thyristor turn-off losses low. Efficiency estimates indicate that this concept could result in converter topologies with power-losses as low as 0.3% rated power, whilst retaining high quality current waveforms and achieving tolerance to both AC and DC faults

DC fault ride-through capability and STATCOM operation of a HVDC hybrid voltage source converter

HVDC transmission systems are becoming increasingly popular when compared to conventional AC transmission methods. HVDC voltage source converters (VSC) can offer advantages over traditional HVDC current source converter topologies; as such, it is expected that HVDC-VSCs will be further exploited with the growth of HVDC transmission. This paper presents the DC fault ride through capability and new STATCOM modes of operation for the recently published Alternate Arm Converter (AAC), intended for the HVDC market. Operation and fault ride through of the converter during a local terminal to terminal short circuit of the DC-Link is demonstrated; during the fault STATCOM operation is also demonstrated

The Extended Overlap Alternate Arm Converter:A Voltage Source Converter with DC Fault Ride-Through Capability and a Compact Design

The Alternate Arm Converter (AAC) was one of the first modular converter topologies to feature DC-side fault ride-through capability with only a small penalty in power efficiency. However, the simple alternation of its arm conduction periods (with an additional short overlap period) resulted in (i) substantial 6-pulse ripples in the DC current waveform, (ii) large DC-side filter requirements, and (iii) limited operating area close to an energy sweet-spot. This paper presents a new mode of operation called Extended Overlap (EO) based on the extension of the overlap period to 60 ◦ which facilitates a fundamental redefinition of the working principles of the AAC. The EO-AAC has its DC current path decoupled from the AC current paths, a fact allowing (i) smooth DC current waveforms, (ii) elimination of DC filters, and (iii) restriction lifting on the feasible operating point. Analysis of this new mode and EO- AAC design criteria are presented and subsequently verified with tests on an experimental prototype. Finally, a comparison with other modular converters demonstrates that the EO-AAC is at least as power efficient as a hybrid MMC (i.e. a DC fault ride-through capable MMC) while offering a smaller converter footprint because of a reduced requirement for energy storage in the submodules and a reduced inductor volume

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation

Background: Acromegaly, an orphan disease usually caused by a benign pituitary tumour, is characterised by hyper-secretion of growth hormone (GH) and insulin-like growth factor I (IGF-1). It is associated with reduced life expectancy, cardiovascular problems, a variety of insidiously progressing detrimental symptoms and metabolic malfunction. Treatments include surgery, radiotherapy and pharmacotherapy. Pegvisomant (PEG) is a genetically engineered GH analogue licensed as a third or fourth line option when other treatments have failed to normalise IGF-1 levels. Methods: Evidence about effectiveness and cost-effectiveness of PEG was systematically reviewed. Data were extracted from published studies and used for a narrative synthesis of evidence. A decision analytical economic model was identified and modified to assess the cost-effectiveness of PEG. Results: One RCT and 17 non-randomised studies were reviewed for effectiveness. PEG substantially reduced and rapidly normalised IGF-1 levels in the majority of patients, approximately doubled GH levels, and improved some of the signs and symptoms of the disease. Tumour size was unaffected at least in the short term. PEG had a generally safe adverse event profile but a few patients were withdrawn from treatment because of raised liver enzymes. An economic model was identified and adapted to estimate the lower limit for the cost-effectiveness of PEG treatment versus standard care. Over a 20 year time horizon the incremental cost-effectiveness ratio was pound81,000/QALY and pound212,000/LYG. To reduce this to pound30K/QALY would require a reduction in drug cost by about one third. Conclusion: PEG is highly effective for improving patients' IGF-1 level. Signs and symptoms of disease improve but evidence is lacking about long term effects on improved signs and symptoms of disease, quality of life, patient compliance and safety. Economic evaluation indicated that if current standards (UK) for determining cost-effectiveness of therapies were to be applied to PEG it would be considered not to represent good value for money

Marine harmful algal blooms (HABs) in the united states: history, current status and future trends

© The Author(s), 2021. This article is distributed under the terms of the Creative Commons Attribution License. The definitive version was published in Anderson, D. M., Fensin, E., Gobler, C. J., Hoeglund, A. E., Hubbard, K. A., Kulis, D. M., Landsberg, J. H., Lefebvre, K. A., Provoost, P., Richlen, M. L., Smith, J. L., Solow, A. R., & Trainer, V. L. Marine harmful algal blooms (HABs) in the united states: history, current status and future trends. Harmful Algae, 102, (2021): 101975, https://doi.org/10.1016/j.hal.2021.101975.Harmful algal blooms (HABs) are diverse phenomena involving multiple. species and classes of algae that occupy a broad range of habitats from lakes to oceans and produce a multiplicity of toxins or bioactive compounds that impact many different resources. Here, a review of the status of this complex array of marine HAB problems in the U.S. is presented, providing historical information and trends as well as future perspectives. The study relies on thirty years (1990–2019) of data in HAEDAT - the IOC-ICES-PICES Harmful Algal Event database, but also includes many other reports. At a qualitative level, the U.S. national HAB problem is far more extensive than was the case decades ago, with more toxic species and toxins to monitor, as well as a larger range of impacted resources and areas affected. Quantitatively, no significant trend is seen for paralytic shellfish toxin (PST) events over the study interval, though there is clear evidence of the expansion of the problem into new regions and the emergence of a species that produces PSTs in Florida – Pyrodinium bahamense. Amnesic shellfish toxin (AST) events have significantly increased in the U.S., with an overall pattern of frequent outbreaks on the West Coast, emerging, recurring outbreaks on the East Coast, and sporadic incidents in the Gulf of Mexico. Despite the long historical record of neurotoxic shellfish toxin (NST) events, no significant trend is observed over the past 30 years. The recent emergence of diarrhetic shellfish toxins (DSTs) in the U.S. began along the Gulf Coast in 2008 and expanded to the West and East Coasts, though no significant trend through time is seen since then. Ciguatoxin (CTX) events caused by Gambierdiscus dinoflagellates have long impacted tropical and subtropical locations in the U.S., but due to a lack of monitoring programs as well as under-reporting of illnesses, data on these events are not available for time series analysis. Geographic expansion of Gambierdiscus into temperate and non-endemic areas (e.g., northern Gulf of Mexico) is apparent, and fostered by ocean warming. HAB-related marine wildlife morbidity and mortality events appear to be increasing, with statistically significant increasing trends observed in marine mammal poisonings caused by ASTs along the coast of California and NSTs in Florida. Since their first occurrence in 1985 in New York, brown tides resulting from high-density blooms of Aureococcus have spread south to Delaware, Maryland, and Virginia, while those caused by Aureoumbra have spread from the Gulf Coast to the east coast of Florida. Blooms of Margalefidinium polykrikoides occurred in four locations in the U.S. from 1921–2001 but have appeared in more than 15  U.S. estuaries since then, with ocean warming implicated as a causative factor. Numerous blooms of toxic cyanobacteria have been documented in all 50  U.S. states and the transport of cyanotoxins from freshwater systems into marine coastal waters is a recently identified and potentially significant threat to public and ecosystem health. Taken together, there is a significant increasing trend in all HAB events in HAEDAT over the 30-year study interval. Part of this observed HAB expansion simply reflects a better realization of the true or historic scale of the problem, long obscured by inadequate monitoring. Other contributing factors include the dispersion of species to new areas, the discovery of new HAB poisoning syndromes or impacts, and the stimulatory effects of human activities like nutrient pollution, aquaculture expansion, and ocean warming, among others. One result of this multifaceted expansion is that many regions of the U.S. now face a daunting diversity of species and toxins, representing a significant and growing challenge to resource managers and public health officials in terms of toxins, regions, and time intervals to monitor, and necessitating new approaches to monitoring and management. Mobilization of funding and resources for research, monitoring and management of HABs requires accurate information on the scale and nature of the national problem. HAEDAT and other databases can be of great value in this regard but efforts are needed to expand and sustain the collection of data regionally and nationally.Support for DMA, MLR, and DMK was provided through the Woods Hole Center for Oceans and Human Health (National Science Foundation grant OCE-1840381 and National Institutes of Health grants NIEHS‐1P01-ES028938–01) and the U.S. National Office for Harmful Algal Blooms with funding from NOAA's National Centers for Coastal Ocean Science (NCCOS) through the Cooperative Institute for the North Atlantic Region (CINAR) (NA14OAR4320158, NA19OAR4320074). Funding for KAL and DMA was provided by the National Oceanic and Atmospheric Administration National Centers for Coastal Ocean Science Competitive Research Program under award NA20NOS4780195 to the Woods Hole Oceanographic Institution and NOAA's Northwest Fisheries Science Center. We also acknowledge support for A.H. from the National Oceanic and Atmospheric Administration [NOAA] Office of Ocean and Coastal Resource Management Award NA19NOS4780183, C.J.G from NOAA-MERHAB (NA19NOS4780186) and (NA16NOS4780189) for VLT Support was also received for JLS, CJG, and VLT from NOAA-NCCOS-ECOHAB under awards NA17NOS4780184 and NA19NOS4780182. This is ECOHAB publication number ECO972

Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly.

This work is licensed under a Creative Commons Attribution 3.0 Unported LicenseBACKGROUND: Long-acting somatostatin analogues delivered parenterally are the most widely used medical treatment in acromegaly. This patient-reported outcomes survey was designed to assess the impact of chronic injections on subjects with acromegaly. METHODS: The survey was conducted in nine pituitary centres in Germany, UK and The Netherlands. The questionnaire was developed by endocrinologists and covered aspects of acromegaly symptoms, injection-related manifestations, emotional and daily life impact, treatment satisfaction and unmet medical needs. RESULTS: In total, 195 patients participated, of which 112 (57%) were on octreotide (Sandostatin LAR) and 83 (43%) on lanreotide (Somatuline Depot). The majority (>70%) of patients reported acromegaly symptoms despite treatment. A total of 52% of patients reported that their symptoms worsen towards the end of the dosing interval. Administration site pain lasting up to a week following injection was the most frequently reported injection-related symptom (70% of patients). Other injection site reactions included nodules (38%), swelling (28%), bruising (16%), scar tissue (8%) and inflammation (7%). Injection burden was similar between octreotide and lanreotide. Only a minority of patients received injections at home (17%) and 5% were self-injecting. Over a third of patients indicated a feeling of loss of independence due to the injections, and 16% reported repeated work loss days. Despite the physical, emotional and daily life impact of injections, patients were satisfied with their treatment, yet reported that modifications that would offer major improvement over current care would be 'avoiding injections' and 'better symptom control'. CONCLUSION: Lifelong injections of long-acting somatostatin analogues have significant burden on the functioning, well-being and daily lives of patients with acromegaly.Chiasma, Inc. 60 Welles Ave, Newton, MA 02 459, USA

Particle growth in urban and industrial plumes in Texas

Particle size distributions and gas-phase particle precursors and tracer species were measured aboard an aircraft in the plumes downwind from industrial and urban sources in the vicinity of Houston, TX during the daytime in late August and early September 2000. Plumes originating from the Parish gas-fired and coal-fired power plant, petrochemical industries along the Houston ship channel, the petrochemical facilities near the Gulf coast, and the urban center of Houston were studied. Most of the particle mass flux advected downwind of Houston came from the industries and electrical utilities at the periphery of the city rather than from sources in the urban core. In SO2-rich plumes that did not contain elevated concentrations of volatile organic compounds (VOCs), particle volume increased with increasing plume oxidation (age) at a rate consistent with condensation and neutralization of the gas-phase oxidation products Of SO2. In plumes that were rich in both SO2 and VOCs, observed particle growth greatly exceeded that expected from SO2 oxidation, indicating the formation of organic particulate mass. In plumes that were enhanced in VOCs but not in SO2, and in the plume of the Houston urban center, no particle volume growth with increasing plume oxidation was detected. Since substantial particle volume growth was associated only with SO2-rich plumes, these results suggest that photochemical oxidation of SO2 is the key process regulating particle mass growth in all the studied plumes in this region. However, uptake of organic matter probably contributes substantially to particle mass in petrochemical plumes rich in both SO2 and VOCs. Quantitative studies of particle formation and growth in photochemical systems containing nitrogen oxides (NOx = NO + NO2 ), VOCs, and SO2 are recommended to extend those previously made in NOx-VOC systems

The state of the Martian climate

60°N was +2.0°C, relative to the 1981–2010 average value (Fig. 5.1). This marks a new high for the record. The average annual surface air temperature (SAT) anomaly for 2016 for land stations north of starting in 1900, and is a significant increase over the previous highest value of +1.2°C, which was observed in 2007, 2011, and 2015. Average global annual temperatures also showed record values in 2015 and 2016. Currently, the Arctic is warming at more than twice the rate of lower latitudes

GlobalHAB - the International SCOR-IOC Science Program on Harmful Algal Blooms. Activities 2020-2021 and Plans for 2021-2022

The partial renovation took place on May 2020. It was conducted virtually due to the Covid-19 pandemic. Since then, all the communication has been conducted by email and virtual meetingsThe GlobalHAB Scientific Steering Committee (SSC) acknowledges the financial and logistic support received from SCOR and IOC during the 2020-2021 period and for the activities postponed to 2022 due to the Covid-19 pandemicsPeer reviewe